SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kane MA. Global status of hepatitis B immunisation. Lancet 1196;348:696.
  • 2
    Lok ASF. Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis Sci 1992; 10:4652.
  • 3
    Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hep Rev 1995; 1:736.
  • 4
    Hoofnagle JH, Di Bisceglie AM. Drug Therapy: the treatment of chronic viral hepatitis. N Engl J Med 1997; 336:347356.MEDLINE
  • 5
    Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hep 1997; 4(suppl:1120.
  • 6
    Bartholomeusz A, Locarnini S. Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine. Int Antiviral News 1997; 5:123124.
  • 7
    Wallace LA, Carman WF. Surface gene variation of HBV: Scientific and medical relevance. Viral Hep Rev 1997; 3:516.
  • 8
    Summers J, Mason W. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 9:403415.
  • 9
    Mason WS, Taylor JM, Hull R. Retroid virus genome replication. Adv Virus Res 1987; 32:3596.MEDLINE
  • 10
    Wang GH, Seeger C. Novel mechanism for reverse transcription in hepatitis B viruses. J Virol 1993; 67:65076512.MEDLINE
  • 11
    Girones R, Miller RH. Mutation rate of the hepadnavirus genome. Virology 1989; 170:595597.MEDLINE
  • 12
    Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1985; 317:489495.MEDLINE
  • 13
    Bartholomeusz A, Schinazi R, Locarnini S. Pathogenesis and significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogue therapy. Viral Hep Rev 1997;in press.
  • 14
    Protzer-Knolle U, Naumann U, Berg T, Bartenschlager R, Hopf U, Meyer zum Buschenfelde K-H, Neuhaus P, et al. Hepatitis B virus with antigenically altered HBsAg is selected by high-dose hepatitis B immuneglobulin after liver transplantation. Hepatology 1998; 27:254263.MEDLINE
  • 15
    Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok ASF. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27:213222.MEDLINE
  • 16
    Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, thomas HC. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336:325329.MEDLINE
  • 17
    Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711713.MEDLINE
  • 18
    Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997; 26:11481153.MEDLINE
  • 19
    Toh H, Hayashida H, Miyata T. Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus. Nature 1983; 305:827829.MEDLINE
  • 20
    Larder BA, Kemp SD, Purifoy DJ. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc Natl Acad Sci U S A 1989; 86:48034807.MEDLINE
  • 21
    Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256:17831790.MEDLINE
  • 22
    Schinazi RF, Lloyd RM, Nguyen MH, Cannon DL, McMillan A, Ilksov N, Chu CK, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993; 37:875881.MEDLINE
  • 23
    Wainberg MA, Salomon H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, et al. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 1995; 9:351357.MEDLINE
  • 24
    Stirk HJ, Thornton JM, Howard CR. A topological model for hepatitis B surface antigen. Intervirology 1992; 33:148158.MEDLINE
  • 25
    Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, et al. Hepatitis B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:2022.MEDLINE
  • 26
    Tillman HL, Trautwein C, Kruger M, Boker K, Schlitt HJ, Condreay L, Deslauriars M, et al. Inhibition of hepatitis B virus replication with lamivudine in patients previously treated with famciclovir after liver transplantation [Abstract]. J Hepatol 26(suppl):153.
  • 27
    Bartholomeusz A, Groenen LC, Locarnini SA. Clinical experience with famciclovir against hepatitis B virus and development of resistance. Intervirology 1997;in press.
  • 28
    Hsu H-Y, Chang M-H, Ni Y-H, Lin H-H, Wang S-M, Chen D-S. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 1997; 26:786791.MEDLINE
  • 29
    De Man RA, Bartholomeusz A, Locarnini S, Niesters HGM, Zondervan PE. The occurrence of sequential viral mutations in a liver transplant recipient re-infected with hepatitis B: primary famciclovir resistance followed by a lethal hepatitis during acquired lamivudine resistance [Abstract]. J Hepatol 1997; 26(suppl:77.
  • 30
    Perillo R, Rakela J, Martin P, Wright T, Levy G, Schiff E, Dienstag J, et al. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post liver transplantation (OLT) [Abstract]. Hepatology 1997; 26 (suppl):260A.
  • 31
    Corey L, Holmes KK. Therapy for human immunodeficiency virus infection. What have we learned? N Engl J Med 1996; 335:11421144.MEDLINE
  • 32
    Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696699.MEDLINE
  • 33
    Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26:216225.MEDLINE
  • 34
    Locarnini SA, Aye TT, Shaw T, De Man R, Angus PW, McCaughan GW, Bartholomeusz AI. The emergence of famciclovir resistant mutations in the hepatitis B virus polymerase during therapy in patients following liver transplantation [Abstract]. Hepatology 1997; 26(suppl:368A.
  • 35
    Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Qunitero JC, Rhodes A, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374:569571.MEDLINE
  • 36
    Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, Graham DJ, et al. Genetic correlates of in vivo viral resistance to Indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996; 70:82708276.MEDLINE
  • 37
    Condra JH, Emmini EA. Preventing HIV-1 drug resistance. Science Med 1997; 4:211.
  • 38
    de Jong MC, Boucher CAB, Galasso GJ, Hirsch MS, Kern ER, Lange JMA, Richman DD. Consensus symposium on combined antiviral therapy. Antiviral Res 1995; 129:529.